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Abstract
This research activity was aimed at the development of composite bioactive scaffolds made of
biodegradable three-arm branched-star poly(ε-caprolactone) (∗PCL), hydroxyapatite nanoparticles
(HNPs) and clodronate (CD), a bisphosphonate that has demonstrated efficacy in the treatment
of various bone diseases and as an anti-inflammatory drug. During the experimental work, the
processing conditions for the fabrication of fibrous meshes, by either electrospinning or wet-
spinning, were optimized. Stemming from a previous research activity on electrospinning of ∗PCL,
∗PCL/HNPs 3D meshes were developed, evaluating the influence of fabrication parameters on the
fibres’ morphology. By exploiting the binding affinity of bisphosphonates for hydroxyapatite, a
methodology was set up for obtaining a physical linkage between CD and HNPs, with the aim
of having a dual bioactive system loaded into ∗PCL fibrous mats. Fibres loaded with either CD
or CD–HNP particles were thus produced and analysed by scanning electron microscopy for their
morphology and by energy dispersive X-ray spectroscopy for their elemental composition. Copyright
 2010 John Wiley & Sons, Ltd.
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1. Introduction
Bisphosphonates (BPs) are a class of bioactive agents
inhibiting bone resorption and ectopic calcification,
widely used in the therapy of diseases caused by altered
metabolism of bone tissue, such as Paget’s disease,
tumour-associated osteolysis and hypercalcaemia, osteo-
porosis and primary hyperparathyrosis (Ezra and Golomb,
2000; Rogers et al., 2000; Martin and Grill, 2000).
*Correspondence to: Emo Chiellini, Laboratory of Bioactive
Polymeric Materials for Biomedical and Environmental
Applications (BIOlab), via Vecchia Livornese 1291, 56010 San
Piero a Grado (Pi), Department of Chemistry and Industrial
Chemistry, University of Pisa, Italy.
E-mail: emochie@dcci.unipi.it
They possess a chemical structure similar to that
of pyrophosphate, an endogenous regulator of bone
mineralization produced by many anabolic processes,
with the advantage of a higher resistance to hydrolysis
and chemical stability. BP effects are due to their
incorporation in the mineral part of bone, enabling
interaction with osteoclasts and osteoblasts. Thanks to
their high affinity for divalent metal ions, BPs bind
strongly to the calcium phosphate crystals of bone
hydroxyapatite (HA), inhibiting their growth, aggregation
and dissolution (Fleisch et al., 1969, 1970; Francis et al.,
1969; Meyer and Nancollas, 1973; Hansen et al., 1976).
Moreover, depending on their molecular structure, BPs
can inhibit bone resorption through various biochemical
pathways with subsequent different effects, such as
inhibition of osteoclast formation, osteoclast apoptosis
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or/and by affecting the metabolic activities of osteoblasts
(Rogers et al., 2000; Van Beek et al., 2002; Horie et al.,
2003).
The major disadvantages associated with systemic use
of the clinically employed BPs are poor absorption and
adverse gastrointestinal effects in oral administration
therapy as well as local tissue damage and irritation at the
injection site (Ezra and Golomb, 2000). A localized and
controlled BP delivery system can allow for improved
bioavailability and safety. It has been reported that
a topical treatment allows for overcoming limitations
associated to systemic use, with the advantages of
having a controlled therapeutic dosage in the region
of interest and BP distribution to avascular areas in
necrotic bone tissue (Astrand and Aspenberg, 2004).
Implanted BP-releasing systems can be employed for
the optimization of hypercalcaemia treatment in tumour-
induced osteolysis (Ezra and Golomb, 2000) and to
improve the local effect in confined dental bone surgery
(Nafea et al., 2008). Furthermore, providing implantable
bioabsorbable systems with BP-releasing features can
prevent osteolytic lesions caused by the inflammatory
processes induced by polymer degradation products
(Huolman and Ashammakhi, 2007).
Various BPs releasing systems for bone applications
have been developed such as coatings for titanium
or stainless-steel screws (Tengvall et al., 2004), BP-
complexed HA implants (Denissen et al., 1997, 2000), BPs
combined to frozen cancellous bone allografts (Jeppsson
et al., 2003) and BP-releasing poly(lactic-co-glycolic) rods
for bone fixation (Huolman and Ashammakhi, 2007). The
possibility of BP encapsulation into microparticles made
of chitosan (Samdancioglu et al., 2006; Patashnk et al.,
2009) or poly(lactic-co-glycolic acid) (Perugini et al.,
2001; Weidenauer et al., 2003; Nafea et al., 2008) has
been also reported.
Poly(ε-caprolactone) (PCL) is a semicristalline polymer
that has been widely proposed for bone regeneration
application because of its biocompatibility and degrada-
tion properties (Williams et al., 2005; Koh et al., 2006;
Rai et al., 2007; Puppi et al., 2010a). In biological condi-
tions, it can be degraded by microorganisms as well as by
hydrolytic mechanisms and its slow degradation rate can
be tuned to match with bone tissue ingrowth (Hutmacher,
2000; Savarino et al., 2007). However, the implantation
of polymer substitutes into bone defects typically presents
various drawbacks, such as lack of immediate adhesion to
the surrounding tissue because of an inflammatory reac-
tion, encapsulation into fibrous tissue and mechanical
strength reduction associated with material degradation
(Taylor et al., 1994; Kokubo et al., 2003; Schiller and
Epple, 2003). The incorporation of HA particles into poly-
mer matrices has been investigated as an effective means
of improving the osteoconductivity and mechanical prop-
erties of bone implants and create a pH buffer against
the acidic degradation products of the polymeric matrices
(Ural et al., 2000; Kikuchi et al., 2004; Kim et al., 2004;
Koh et al., 2006; Puppi et al., 2010a).
This research activity was aimed at the development
of new BP-releasing bioabsorbable scaffolds for bone
tissue-engineering applications. Clodronic acid disodium
salt (clodronate, CD), an efficient anti-osteolytic agent
with approved clinical record and low rate of adverse
events (Selander et al., 1996; Fleisch, 2000; Huolman
and Ashammakhi, 2007), was chosen in this study as
a BP model. CD has also demonstrated efficacy as
anti-inflammatory agent and in stimulating osteoblast
differentiation in osteoblast-like and pluripotent mes-
enchymal cell culture (Horie et al., 2003; Itoh et al.,
2003). The three-dimensional (3D) carriers developed
within this experimental project are polymeric and com-
posite fibrous meshes produced by either electrospinning
or wet-spinning techniques. Since fibre dimension and
mesh porosity can greatly affect drug release kinetics, our
aim was to develop BP-loaded polymeric meshes with a
different structural scale and texture by employing the two
techniques mentioned. A three-arm branched star poly (ε-
caprolactone) (∗PCL) (Balakrishnan et al., 2004, 2006),
a biocompatible polymer which has been already inves-
tigated for the production of electrospun fibrous meshes
for tissue engineering applications (Puppi et al., 2010b),
was employed. The processing conditions for the produc-
tion of ∗PCL meshes loaded with either HA nanoparticles
(HNPs) or CD were optimized and correlated to mesh
morphology. Exploiting the binding affinity of BPs for HA
(Rogers et al., 2000; Leu et al., 2006), a methodology for
obtaining a physical linkage between CD and HNPs was
investigated. The incorporation of particles of such com-
plex into ∗PCL fibres was also studied in order to introduce
a further control over drug release as well as to increase
the osteoconductivity of polymer meshes. The meshes
produced were characterized for their morphology by
scanning electron microscopy (SEM) and for composition
by energy dispersive X-ray spectroscopy (EDS).
2. Materials and methods
2.1. Materials
Three-arm branched star poly(ε-caprolactone) (∗PCL,
MW 189 000 Da) was kindly supplied by Michigan
Biotechnology Institute; HA nanoparticles (HNPs, size
<200 nm) were bought from Sigma-Aldrich and clodronic
acid disodium (CD) was kindly supplied by Abiogen
Pharma-Pisa (Italy). All the solvents and chemical
reagents were purchased from Sigma-Aldrich (Italy) and
used as received.
2.2. Preparation of CD–HNP complex and study
of loading efficiency
500 mg CD was dissolved in 10 ml distilled water at
room temperature with stirring for 2 h. Then, 250 mg
HNPs powder were added to the CD solution and the
mixture was incubated under gentle stirring for 1 h at
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room temperature. CD binding efficiency was evaluated
by measuring the free CD in the supernatant. Free CD was
complexed with copper ions (Cu2+) in nitric acid solution,
and its concentration was determined by ultraviolet
spectrophotometry (UV) at 236 nm (standard curve,
0.025–1.0 mM; R2 = 0.993) as described by Ostovic´ et al.
(1993). The binding efficiency (η) of the physical reaction
between CD and HNPs was calculated as follows:
η = (CDi − CDf)/CDi
where CDi is the input drug and CDf is the free drug in
the supernatant.
2.3. Development of fibrous meshes by either
electrospinning or wet-spinning
Polymer and composite fibrous meshes were produced by
processing plain ∗PCL solutions or suspensions of HNPs,
CD or CD–HNP particles in ∗PCL solution, respectively.
The processing conditions for the production of fibres by
either electrospinning or wet-spinning were investigated.
The prepared meshes were analysed for their morphology
and composition by SEM and EDS, respectively.
2.3.1. Preparation of polymer solutions and
polymer/CD/HNP mixtures
∗PCL was dissolved in acetone at 40 ◦C, under gentle
stirring for 2 h to obtain homogeneous solutions of various
concentrations. For the production of composite fibres,
CD, HNPs or CD–HNP particles were added to the polymer
solution and left under vigorous stirring for 2 h to achieve
their homogeneous dispersion.
On the base of some preliminary investigations, the
weight ratio between HNPs and ∗PCL in solutions for the
production of fibres loaded with either HNPs or CD–HNP
particles, was chosen to be 25% by weight. Therefore,
considering the binding efficiency between CD and HNPs,
the theoretical weight ratio between CD and ∗PCL in
the solutions for the production of fibres loaded with
CD–HNPs was 0.075. This value was employed also for
the fabrication of CD-loaded ∗PCL fibres.
2.3.2. Production of electrospun fibre meshes
A 15% w/v ∗PCL solution was placed in a syringe equipped
with a metallic needle, with an inner diameter (i.d.) of
0.84 mm, and the solution feeding rate was controlled
by a syringe pump (KDS100, KD Scientific, MA). Using a
semi-commercial high-voltage power supply, an electric
field was applied between the metallic needle of the
syringe and an electrical grounded aluminium collector.
The applied voltage was 25 kV and the distance from
the needle tip to the collector 15 cm. The variation of
the processing conditions for the production of ∗PCL
meshes was evaluated in order to optimize the fibres
mesh morphology. In particular, the influence of solution
feed rate was investigated in the range 1–16 ml/h. The
electrospun mats were removed, placed in a vacuum
chamber for at least 48 h to allow the evaporation of the
residual organic solvent and then stored in a desiccator.
2.3.3. Production of 3D wet-spun fibre meshes
A polymer solution was loaded into a plastic syringe
(5 ml) with a metallic needle (0.5 mm i.d.) attached to
it. The syringe was connected to a programmable syringe
pump (KD Scientific, World Precision Instruments, UK)
to inject the polymer solution at controlled pumping
rate to allow the formation of non-woven web directly
into the coagulation bath. The non-woven web was
formed during the processing by the random movement
of the coagulation bath. Various processing parameters,
such as solvent, polymer concentration, coagulation bath
and solution flow rate, were varied to optimize fibre
morphology. Either acetone or chloroform was employed
as solvent and methanol, ethanol and water were tested
for the coagulation bath. Spun meshes were left in
the coagulation bath for 24 h, then removed, placed
in a vacuum chamber for 48 h and finally stored in a
desiccator.
2.4. Scanning electron microscope (SEM) and
energy dispersive X-ray spectroscopy (EDS)
analysis
Samples were gold-coated using a sputter-coater set at
15 mA for 20 min and mesh morphology was investigated
by using SEM instruments (Leica 360; FEI Nova 200).
Mesh elemental composition was investigated by EDS
analysis (EDAX Pegasus X4M), based on the energy
and intensity distribution of X-ray signals generated by
the electron beam striking the surface of the specimen.
Three random areas (300 × 400 µm) of each sample were
analysed for their elemental composition.
3. Results and discussion
3.1. Development of CD–HNPs complex
The high affinity of BPs for HA, due to their ability to
form a 3D structure with divalent metal ions (Rogers
et al., 2000; Leu et al., 2006), is the basis of their bone-
targeting property. A few recent experimental studies
have proposed HA as the carrier for the controlled delivery
of BPs adopting different strategies, such as incorporation
of BPs into HA crystals (McLeod et al., 2006; Boanini
et al., 2007) or BP–HA physical binding (Seshima et al.,
2006; Ong et al., 2008).
In the present study, we investigated a straightforward
simple method for obtaining a physical binding between
CD and HNPs with η (yield) of around 15%. Figure 1
shows micrographs of HNPs and CD powders as well as
that of CD–HNPs powder, recovered after centrifugation
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Figure 1. SEMmicrographs: (a) HNPs powder; (b) CD powder; (c) CD–HNPs powder. (d) Representative EDS spectrum of CD–HNPs
complex
of the reaction mixture. Compared to the native CD and
HNP morphology, in the micrograph of the recovered
CD–HNPs a coating of CD structures with HNPs can be
detected, thus indicating the formation of the complex
CD–HNPs at least in the dry powder state (Figure 1c).
EDS analysis of the recovered CD–HNPs powders
showed the presence of chlorine (Cl) and sodium
(Na), correlated to the presence of CD, and calcium
(Ca), associated to HNPs (Figure 1d). Moreover, from
comparison among spectra of different randomly taken
fields, it appears that CD was uniformly distributed along
powder specimens (data not shown).
3.2. Development of ∗PCL-based electrospun
meshes
In the last 10 years, electrospinning has been gaining
a widespread interest for applications in drug delivery
and tissue engineering. Electrospinning enables great
flexibility in materials selection, drug-loading methods
and choice of the appropriate loading agent. These,
together with various inherent features of electrospun
meshes (such as high surface area : volume ratio and high
and interconnected porosity), can enhance drug loading
and mass transfer properties, offering a broad spectrum
of advanced design solutions for the fine control of drug
release kinetics (Ashammakhi et al., 2007; Detta et al.,
2010). In the last years a few studies have investigated
the possibility of incorporating therapeutic and bioactive
agents into electrospun fibres without affecting mesh
morphology and the bioactivity of loaded agents (Cui
et al., 2006; Piras et al., 2006; Xie and Wang, 2006; Xu
et al., 2006; Zheng-Ming et al., 2006; Nie and Wang,
2007; Maretschek et al., 2008; Piras et al., 2008; Puppi
et al., 2009). Moreover, electrospun mats composed of
randomly orientated fibres with diameters down to
the nanometer scale are suitable for replicating the
physical structure of the extracellular matrix of biological
tissues, and they have been shown to influence in vitro
cell adhesion, proliferation and phenotypic behaviour
(Bhattarai et al., 2004; Shin et al., 2004; Fujihara et al.,
2005; Badami et al., 2006; Stitzel et al., 2006; Martins
et al., 2007, 2009a, 2009b; Araujo et al., 2008; da Silva
et al., 2008; Pinho et al., 2009).
During the present research activity, we investigated
the processing of suspensions of HNPs, CD or CD–HNPs in
∗PCL solution by applying the electrospinning conditions
optimized in a previous related study on ∗PCL electrospun
fibres (15% w/v polymer concentration, V = 25 kV and
d = 15 cm) (Puppi et al., 2010b) and by studying the
influence of solution feed rate on mesh morphology.
3.2.1. ∗PCL/HNPs electrospun meshes
In the recent years, a few published works have reported
the inclusion of HA particles into electrospun polymer
fibres as means for improving mesh osteoconductivity and
mechanical properties (Ito et al., 2005; Hae-Won et al.,
2006; Catledge et al., 2007; Dai and Shivkumar, 2007).
As shown in Figures 2a–c, the addition of HNPs to the
electrospinning solution led to the formation of fibre
morphology defects. By increasing the feed rate, the
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Figure 2. SEM micrographs of ∗PCL-based electrospun samples (C∗PCL = 15% w/v, V = 25 kV). ∗PCL/HNPs composite meshes: (a) F
= 16 ml/h; (b) F = 8 ml/h; (c) F = 4 ml/h. CD-loaded ∗PCL meshes: (d) F = 16 ml/h; (e) F = 8 ml/h; (f) F = 2 ml/h. ∗PCL meshes
loaded with CD–HNP particles: (g) F = 16 ml/h; (h) F = 4 ml/h; (i) F = 16 ml/h, high magnification
formation of defects in the analysed meshes was inhibited.
EDS analysis confirmed the presence (Figure 3a) and
the homogeneous distribution of phosphorus (P) and Ca
correlated to HNPs loading.
3.2.2. CD-loaded ∗PCL electrospun meshes
SEM analysis of electrospun CD-loaded ∗PCL meshes
showed a fibrous structure characterized by fibre defects,
in the form of beads along the fibres (Figures 2d–f). Both
the number per unit area and the size of beads were
gradually decreased by decreasing the solution feed rate
from 16 ml/h to 1 ml/h. EDS analysis was performed to
investigate whether heterogeneous drug distribution was
responsible for mesh defects and to analyse the beads’
composition. Spectra of CD-loaded meshes displayed
low-energy peaks corresponding to the elements of CD
(Figure 3b). This can be related to the low amount of CD
added to the polymer solution and/or to the distribution
of the drug in the fibre section. Moreover, there were no
remarkable differences between the composition of fibres
and beads, indicating that the formation of such defects
was due to the electrospinning setting, which initially
was not optimized, and not to a heterogeneous drug
distribution into the mesh microstructure.
3.2.3. ∗PCL meshes loaded with CD–HNP
particles
Fibrous meshes loaded with CD–HNP particles were
produced with no remarkable influence of the feeding
rate on fibre morphology (Figure 2g, h). Figure 3c shows
a representative EDS spectrum of this kind of mesh;
comparing the EDS spectra taken from different areas
in the same sample, the elements composing both CD
(P, Cl, Na) and HNPs (P, Ca) were uniformly distributed
in the analysed meshes. However, some microaggregates
(Figure 2i) with morphology similar to that observed in
CD–HNPs powder (Figure 1c) were observed in high-
magnification micrographs. EDS analysis revealed that
these microaggregates were mainly composed of the
elements of CD and HNPs (Figure 3d). The presence
of such microaggregates, mainly composed of CD–HNP
particles not incorporated into ∗PCL fibres, may influence
the release kinetics of the loaded meshes, contributing to
a possible initial burst release.
3.3. Development of wet-spun meshes
Wet-spinning is a non-solvent-induced phase inversion
technique allowing for polymer fibre production through
an immersion–precipitation process. In detail, a contin-
uous polymer fibre is produced by precipitation of a
polymer solution filament in a coagulation bath composed
of a poor solvent (non-solvent) or a non-solvent–solvent
mixture with respect to the processed polymer. An homo-
geneous solution filament, composed of polymer, solvent
and possible additives, solidifies because of polymer des-
olvation, caused by solvent–non-solvent exchange.
A number of studies have reported the development
of wet-spun fibres made of natural polymers, such as
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Figure 3. Representative EDS spectra of electrospinning samples: (a) ∗PCL/HNPs composite mesh; (b) CD-loaded ∗PCL mesh;
(c) ∗PCL mesh loaded with CD–HNPs; (d) microaggregate into ∗PCL mesh loaded with CD–HNPs
Figure 4. Wet spun ∗PCL (F = 1.75 ml/h): (a) photograph of 3D mesh; (b) SEM micrograph of mesh; (c) SEM micrograph of single
fibre
chitosan (Tuzlakoglu et al., 2004; Tuzlakoglu and Reis,
2008) and regenerated silk fibroin (Yao et al., 2001; Um
et al., 2004; Lee et al., 2007). In recent years, some
research has proposed wet-spun fibres as carriers for
drug release, such as either chitosan (Denkbas et al.,
2000) or PLLA fibres (Gao et al., 2007) loaded with 5-
fluorouracil. This technique was also proposed to develop
scaffolds for tissue-engineering applications, based in PCL
fibres (Williamson and Coombes, 2004), braided PLLA
or chitosan fibres (Zhang et al., 2007) and starch-based
fibres (Tuzlakoglu et al., 2009).
During this experimental activity, the wet-spinning
process for obtaining the ∗PCL-based wet-spun fibres
loaded with HNPs, CD or CD–HNPs were investigated
by improving the processing conditions, such as the
solvent–non-solvent system, polymer concentration and
solution feed rate.
3.3.1. ∗PCL wet-spun meshes
The production of fibrous meshes by wet-spinning was
tested with ∗PCL solutions and two different solvents
(acetone and chloroform), as well as various polymer
concentrations (10–20% w/v) and three different non-
solvents (methanol, ethanol, water), to optimize the
processing conditions. When chloroform was employed
as solvent, proper polymer coagulation was not achieved
for any of the above-mentioned non-solvents. Employing
acetone as solvent and ethanol as non-solvent, phase
inversion took place, allowing for the coagulation of the
spun solution in the form of a polymer fibre. In this
case, the polymer concentration giving by the best fibre
morphology was found to be 15% w/v. The influence
of solution flow rate on fibre morphology was further
studied in the range 1.5–3.5 ml/h. The results showed
that the fibres’ morphology was improved when using
the flow rate of 1.75 ml/h (Figure 4a). This condition
produced a fibre diameter in the range 100–250 µm
and a porous fibre structure with a pore size of few
micrometers (Figure 4b, c). Moreover, the fibres looked
fused at fibre–fibre contact points, forming a cohesive
non-woven web.
Upon immersion of a polymer solution into a
coagulation bath, the non-solvent diffuses into the
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Figure 5. Wet spun ∗PCL-based meshes: (a) SEMmicrograph of ∗PCL/HNPsmesh; (b) SEMmicrograph of fibre surface of ∗PCL/HNPs
mesh; (c) EDS spectrum of ∗PCL/HNPs fibre; (d) SEM micrograph of CD-loaded ∗PCL mesh; (e) SEM micrograph of fibre surface of
CD-loaded ∗PCL mesh; (f) EDS spectrum of CD-loaded ∗PCL fibre; (g) SEM micrograph of ∗PCL mesh loaded with CD–HNP particles;
(h) SEM micrograph of fibre surface of ∗PCL mesh loaded with CD–HNP particles; (i) EDS spectrum of ∗PCL fibre loaded with
CD–HNPs
polymer solution, whereas the solvent diffuses into the
bath. Solvent–non-solvent counter-diffusion lowers the
polymer solubility and induces a phase separation into a
polymer-rich phase and a polymer-lean phase. A dense
polymer matrix surrounding the dispersed polymer-lean
droplets, which will form the pores, is consequently
formed. Usually a dense, non-porous layer, due to the
instantaneous non-solvent diffusion into the polymer
solution, is observed at the interface with the coagulant
(Tsay and Mchugh, 1990, 1992; Wienk et al., 1996). As
reported in the literature, the formation of a spongy
morphology with a porous surface interfacing with the
coagulating fluid is due to delayed liquid–liquid demixing
(Wienk et al., 1996; Barton et al., 1997).
What is observed in the SEM micrographs of wet-spun
∗PCL fibres, concerning both the porous morphology of
the fibre outer surface and the bonding at the fibre–fibre
contact points, indicates that in our case the inversion
phase process was governed by delayed precipitation and
that the filament was not completely solidified when it
settled at the bottom of the bath container.
On the basis of this preliminary investigation, the
optimized processing conditions were 15% w/v polymer
concentration, acetone as solvent, ethanol as non-solvent
and 1.75 ml/h flow rate. The composition of the starting
suspensions selected for the production of ∗PCL fibres
loaded with HNPs, CD or CD–HNP particles was the
same as that already employed for the electrospinning
technique.
3.3.2. ∗PCL/HNPs wet-spun meshes
3D fibrous meshes of ∗PCL/HNPs composite fibres were
fabricated by the coagulation of a filament of HNPs
suspension in the polymer solution. SEM analysis from
∗PCL/HNPs meshes revealed a more narrow fibre size
distribution, comparing to bare polymer matrices, with
fibre diameters in the range 100–200 µm. In addition,
∗PCL/HNPs meshes showed a less porous surface and no
fusion between fibres at the crossing points (Figure 5a, b).
It is known that the additives loaded into polymer
solution may have an effect on the final morphology
of the polymeric porous systems produced by phase
inversion. Their presence is mainly reflected on both
process thermodynamics and kinetics (Strathmann et al.,
1975; Reuvers and Smolders, 1987; Mulder, 1996; Kim
and Lee, 1998).
In this case, a possible effect of the addition of HNPs
to polymer solution could be a faster solidification of
the filament, generating a less porous fibre morphology.
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In a speculative manner, this phenomenon may be
attributed to a pre-existing interaction between polymer
and additive, which indeed has an effect on polymer
solvation and consequently on the coagulation process.
Figure 5c shows a representative EDS spectrum of
HNPs-loaded ∗PCL fibres. Chemical composition analysis
of fibre surface revealed the presence and homogeneous
distribution of P and Ca elements, unequivocally
associated with the presence of HNPs.
3.3.3. CD-loaded ∗PCL wet-spun meshes
The possibility of producing wet-spun fibres loaded with
bioactive agents has been shown in a few studies over
recent years (Denkbas et al., 2000; Gao et al., 2007;
Chang et al., 2008). In the present study, 3D CD-loaded
fibre meshes were successfully produced by coagulation
of a filament of CD/∗PCL suspension (Figure 5d, e).
The addition of CD had a remarkable influence on
mesh morphology: the fibre dimensions changed to a
wider diameter range (150–350 µm) and no fusion was
observed between fibres at the crossing points. The
reduced surface porosity and the absence of fibre–fibre
fusion suggest that a faster liquid–liquid demixing takes
place in comparison to the processing of bare polymer
fibres.
EDS analysis (Figure 5f) confirmed the presence and
the homogeneous distribution of CD diagnostic atomic
elements (Na, P and Cl). In addition, some white spots
were observed on the fibre surfaces and they were
analysed for their elemental composition to determine
whether they were mainly composed of elements of CD.
The small differences in intensity of analogue energy
peaks in the spectra of the wide fibre surface areas and
the white spots revealed that there was no significant drug
segregation onto the fibre surface.
3.3.4. Wet-spun fibres loaded with CD–HNP
particles
By processing a suspension of CD–HNP particles in ∗PCL
solution, composite meshes with fibre diameters in the
range 100–200 µm were produced. As shown by SEM
analysis (Figure 5g, h), the fibre surface was characterized
by a porous morphology and appeared to be covered with
aggregates of CD–HNP particles. This was confirmed by
EDS analysis of the fibre surface, showing high-energy
peaks associated with elements composing CD and HNPs
(Na, Cl, P and Ca) (Figure 5i). Similarly to what was
observed for fibres loaded with either HNPs or CD,
the surface porosity was reduced in comparison with
unloaded fibres and the fibres did not show fusion at the
crossing points.
3.4. General remarks on the results achieved
This section aims to provide a generalized discussion of
the techniques utilized for the production of 3D polymeric
scaffolds.
By applying the two different techniques investigated,
we obtained 3D meshes composed of ∗PCL fibres with
different texture scales and loaded with bioactive agents
for potential application in bone repair. In both cases, the
addition of loading agents (HNPs, CD or CD–HNPs) to
the polymer solutions affected the morphology of the final
fibrous structure. In detail, the addition of either HNPs or
CD led to the formation of defects along the electrospun
fibres, which could be minimized by varying the solution
feed rate and affected the wet-spinning solidification
process, causing changes in mesh morphology in terms of
fibre–fibre contact point, fibre diameter and fibre porosity.
In the case of meshes produced from suspensions of
CD–HNP particles, aggregates mainly composed of CD
and HNPs elements, which were not incorporated into
polymer fibres, were observed in both electrospun and
wet-spun samples. The inclusion of CD–HNP particles
into fibres may present advantages over the loading of
CD alone, such as an increase in osteoconductivity, due to
the presence of the inorganic phase, and the introduction
of a further control over CD release kinetics because
of the physical binding between CD and HA. However,
the presence of such microaggregates should be taken
into consideration when studying drug release kinetics,
because it may influence the behaviour of the loaded
meshes, contributing to a possible initial burst in the
release profile. In addition, such aggregates may cause
great loss of the drug and the inorganic phase due to their
solubilization or leaching during the pre-treatment stages
before in vivo implantation (e.g. sterilization, in vitro
scaffold preconditioning) causing a decrease of the actual
loading of the implant.
During this study, it was observed that the developed
electrospun fibres have a diameter of a few micrometers,
while wet-spun fibres have a diameter of a few
hundred micrometers. As the diameter of polymeric
fibres shrinks, a much larger specific surface area
can result, and the ratio of the polymer chains
and of possible functional groups exposed to the
surrounding environment can proportionally increases.
As a consequence, more binding sites to cell membrane
receptors are available, favouring cell attachment and
proliferation, and mass transport phenomena throughout
the fibrous construct are enhanced, improving cell
nutrients and waste exchange (Zhang et al., 2005;
Detta et al., 2010). In addition, such influence on the
mechanism and/or kinetics of the transport processes
in the porous system will likely increase the material
degradation rate and the release kinetics of loaded
bioactive factors. However, it should be taken into account
that the non-woven ultra-fine fibre structure typical of
electrospun meshes presents pores in the nanometer scale,
or in any case with the pore dimensions not larger than
few micrometers. It is possible that this factor limits
cell migration through the mesh, such that nanofibre
constructs have been also proposed as an effective means
to prevent post-surgery abdominal adhesion by providing
a barrier function (Sill and von Recum, 2008). In
addition, electrospinning enables polymeric meshes with
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a thickness not larger than few millimeters to be obtained,
while wet-spun constructs can have a thickness of some
centimeters. In order to combine the advantages of each
kind of fibre and minimize the aforementioned concerns,
it would be interesting to combine the electrospun
and wet-spun fibres developed during this study into
a multi-scale network structure. Previous studies on
such tissue-engineering scaffolds showed that electrospun
ultrafine fibres can enhance the biological performance
of the 3D microfibrous structure (obtained by either
wet-spinning or rapid prototyping), which provides the
required mechanical stability (Tuzlakoglu et al., 2005;
Martins et al., 2009a). Moreover, on the hypothesis that
the remarkable difference in fibre diameter between
electrospun and wet-spun fibres significantly affects mass
transfer phenomena, by modulating the ratio between
these two kinds of fibres constituting a multi-scale
construct it would be possible to vary the release kinetics.
Another aspect to be considered is the need for
improvement of the wet-spinning process employed
during the present study for the production of 3D
structures. Considering that the non-woven morphology
was obtained through a continuous random motion of
the coagulation tank made by hand, the final fibrous
texture depends on the ability of the operator, and the
process can be tiring (a scaffold of 5 mm in thickness
is produced in around 30 min, applying the processing
conditions optimized in this study). The employment of an
automated system for computer control of the tank motion
could significantly increase the production efficiency and
improve the reproducibility of the mesh morphology. This
is an important issue for future research activity.
4. Conclusions
Considering the multifunctional biological activity of BPs,
we believe that a BP-releasing feature can greatly improve
the performance of tissue-engineering scaffolds in inhibit-
ing bone resorption associated with various bone diseases,
such as tumour-associated altered bone metabolism or
osteoporosis. It would play a main role in preventing
osteolytic lesions caused by polymer degradation prod-
ucts, inhibiting post-implantation inflammatory reactions,
and in stimulating bone regeneration. This research activ-
ity was aimed at the set-up of optimal conditions for the
production of CD-loaded biodegradable fibrous scaffolds.
In order to have control over the release kinetics of the
active agent through the tuning of fibre dimensions and
mesh porosity, we have developed fibrous mats with dif-
ferent structural scales and textures, by applying either
electrospinning or wet-spinning techniques. ∗PCL, a novel
star branched polymer, was investigated for the produc-
tion of CD-releasing fibre meshes. Moreover, in order to
introduce a further control over drug release based on
CD affinity for HA, we developed a methodology for the
obtainment of CD–HNP complex particles, achieving 15%
binding affinity. Composite ∗PCL fibre meshes, obtained
by processing suspensions of either HNPs or CD–HNP
particles in polymer solution, were successfully produced.
The inclusion of the active agents into polymer fibres
influenced mesh morphology in the case of both electro-
spinning and wet-spinning. EDS analysis confirmed the
presence of the active agents, loaded into the fibrous
meshes. The developed methodologies appear simple and
operator-friendly and led to highly reproducible results.
The study is presently ongoing for evaluation of
the applicability of the developed meshes as scaf-
folds for bone repair and tissue engineering. All
the prepared scaffolds are currently under character-
ization for their biodegradation profile, drug release
kinetics, mechanical properties, biocompatibility and
osteoconductivity.
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